A Surprising Vaccine Rival May Upset the Dreams of Anyone Holding Moderna and Pfizer Stock
A small team of 10 researchers began designing vaccine candidates shortly after the genetic sequence of the SARS-CoV-2 virus was made public last January. For the past decade, the team had worked on vaccines for the Zika virus and Ebola, as well as another coronavirus, MERS. They knew others working on a COVID vaccine would beat them to market, but they had their sights set on a bigger prize.
This week, that team injected its vaccine candidate into the first human. If it works, it could throw the sales estimates for Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and others up in the air. It seems while the well-known biotech and blue chip drugmaker were winning the battle against the novel coronavirus, this unsung group was trying to end the war.
Image source: Getty Images.
Source Fool.com
